Lilly(Eli) & Co

+1.20 (+0.51%)

FDA Approves Verzenio As The First And Only Cdk4/6 Inhibitor For Certain People With Breast Cancer

Published: 10/13/2021 10:57 GMT
Lilly(Eli) & Co (LLY) - FDA Approves Verzenio® (abemaciclib) As the First and Only Cdk4/6 Inhibitor for Certain People With Hr+ Her2- High Risk Early Breast Cancer.
Eli Lilly - Verzenio Labelling Contains Warnings, Precautions for Diarrhea, Neutropenia, Interstitial Lung Disease, Hepatotoxicity.
Eli Lilly - Verzenio Labelling Also Contains Warnings, Precautions for Venous Thromboembolism, Embryo-fetal Toxicity.